NVS Stock Analysis: Buy, Sell, or Hold?
NVS - Novartis AG
$150.93
-0.63 (-0.42%)
▼
5d:
+1.21%
30d:
+1.92%
90d:
-2.53%
BUY
MODERATE Confidence
Analysis Updated: Jun 16, 2026 12:00 AM ET
Earnings: Jul 16, 2026
28d
Get Alerted When NVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NVS shows positive signals but monitor for confirmation. Market pricing in 0.6% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NVS shows positive signals but monitor for confirmation. Market pricing in 0.6% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$227.89
Based on 8.2% avg growth
INTRINSIC VALUE TODAY
$141.50
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NVS is currently trading at $150.93, which is considered slightly high relative to its 30-day fair value range of $146.53 to $151.83. The stock's valuation (Forward PE: 15.2) is in line with its historical norms (15.5). Remarkably, the market is currently pricing in an annual earnings decline of 0.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NVS is in a uptrend. The price is approaching resistance at $154.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NVS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVS is in a uptrend. The price is approaching resistance at $154.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NVS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$146.53 -
$151.83
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($153.87)
Trading Range Analysis
30-Day Trading Range
$146.53 -
$151.83
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$142.26
Resistance Level
$154.71
Current Trend
Uptrend
Technical data as of
Jun 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.19
Wall Street Target
$153.87
(+1.9%)
Revenue Growth (YoY)
-0.7%
Earnings Growth (YoY)
-9.3%
Profit Margin
23.9%
Valuation Discount vs History
-0.6% cheaper
PE vs Historical
15.2 vs 15.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.6%
(market-implied from PE analysis)
1-Year Target
$150.02
(-1%)
2-Year Target
$149.12
(-1%)
3-Year Target
$148.23
(-2%)
3-Yr Target (if PE normalizes)
(PE: 15→16)
$151.21
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 12.4%)
$307.22
(+104%)
Base:
(SPY PE: 15.2, Growth: 12.4%)
$214.33
(+42%)
Bear:
(PE: 12.9, Growth: 12.4%)
$182.18
(+21%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 21.68 | Current EPS (TTM): $6.99
Bull Case
$236.91
(+57%)
Analyst growth 42.1%, PE expands to 23.9
Base Case
$215.37
(+43%)
Market implied 42.1%, PE stable at 21.7
Bear Case
$103.06
(-32%)
Severe decline -20.0%, PE contracts to 18.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.2 to 15.5
Stabilization Target:
$153.96
(+2.0%)
PE Expansion Potential:
+2.0%
Share & Embed Analysis
Last updated: June 16, 2026 9:10 PM ET
Data refreshes hourly during market hours. Next update: 10:10 PM
Data refreshes hourly during market hours. Next update: 10:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1216 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 55 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 63 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$221 | 62 BUY |
